Jeremy Bender

Jeremy Bender is CHIEF EXECUTIVE OFFICER of Day One Biopharmaceuticals, Inc., which holds 113 of the 115 filings, published between July 6, 2022 and July 8, 2026. The other 2 come from Aura Biosciences, Inc. and Mereo BioPharma Group plc, where Bender is a Director.

The record is best read through its option exercises (42) and 39 other filings, more numerous than the 32 sales. Those total EUR 4,844,527, with a median of EUR 112,138, and no purchase appears. One clearly exceeds the rest: EUR 1,167,911 on May 1, 2024, ahead of EUR 254,927 on October 3, 2022 and EUR 253,234 on November 1, 2022.

The volume keeps growing: 16 filings in 2022, 24 in 2023, 28 in 2024, then 34 in 2025. A total of 24 filings fall in the last twelve months, 2 of them sales. The publication delay is 3 days at the median, across 114 dated filings.

There are 32 of Bender's market trades within 30 days of a trade by Charles N. York II and 27 by Samuel C. Blackman, each time in the same direction.